ArticleCureus2026
Efficacy of Nutrilite® All Plant Protein in Postprandial Glycemic Control: A Non-randomized, Controlled, Crossover Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose balance is essential for life and health. It's regulated by organs that absorb glucose after eating and by the liver that produces glucose during fasting. This study aimed to investigate the acute effect of Nutrilite® All Plant Protein (APP), administered as a preload in 250 mL spiced buttermilk, on glycemic response to a standardized 75 g oral glucose load in individuals with compromised blood glucose levels. The impact of APP, a plant-based dietary protein formulation, was assessed using a non-randomized, fixed-sequence, controlled crossover design to evaluate its potential as a nutritional intervention to improve glycemic response. Fourteen participants were enrolled in the study. Efficacy analyses were conducted in the complete paired efficacy population, defined as participants with usable paired glucose measurements at both intervention visits and all predefined time points (n = 10). Blood glucose spikes were better regulated with APP preload at almost all time points compared to the reference product (glucose). In this acute oral glucose tolerance test (OGTT)-based setting, participants maintained glucose values within the normoglycemic range for a longer duration after the APP preload condition than after the glucose-only reference condition. In the complete paired efficacy population (n = 10), the average incremental area under the curve (iAUC) for the reference product was 3049.5 ± 1290.45. In contrast, the average iAUC for APP combined with the reference product was 700.5 ± 688.74, representing a 78% reduction. This decrease in iAUC was statistically significant (p < 0.005). The significant reduction in iAUC suggests that APP may blunt acute glycemic excursions after a 75 g oral glucose challenge. These findings should not be directly extrapolated to mixed-meal settings without additional vehicle-controlled and meal-based studies. Furthermore, the findings should be interpreted as an acute reshaping of the OGTT glucose response curve rather than as evidence of uniformly improved glycemic control throughout the full 120-minute period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.